I-MAB BIOPHARMA
I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. .
I-MAB BIOPHARMA
Social Links:
Industry:
Biotechnology Pharmaceutical Product Research
Founded:
2016-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.i-mabbiopharma.com
Total Employee:
51+
Status:
Active
Contact:
+862160578000
Email Addresses:
[email protected]
Total Funding:
815 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress Wordpress Plugins Nginx IPv6 Microsoft Azure DNS
Similar Organizations
InventisBio
InventisBio is a clinical-stage biotech company dedicated to the research and development of innovative small-molecule drugs.
SalubrisBio
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Visen Pharmaceuticals
Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-03-23 | Tianjing Biotechnology (Shanghai) Co | Tianjing Biotechnology (Shanghai) Co acquired by I-Mab Biopharma | N/A |
Investors List
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - I-Mab Biopharma
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Post-IPO Equity - I-Mab Biopharma
Alyeska Investment Group
Alyeska Investment Group investment in Post-IPO Equity - I-Mab Biopharma
Avidity Partners
Avidity Partners investment in Post-IPO Equity - I-Mab Biopharma
Lake Bleu Capital
Lake Bleu Capital investment in Post-IPO Equity - I-Mab Biopharma
OrbiMed
OrbiMed investment in Post-IPO Equity - I-Mab Biopharma
GIC
GIC investment in Post-IPO Equity - I-Mab Biopharma
Octagon Capital Partners
Octagon Capital Partners investment in Post-IPO Equity - I-Mab Biopharma
Invus
Invus investment in Post-IPO Equity - I-Mab Biopharma
Cormorant Asset Management
Cormorant Asset Management investment in Post-IPO Equity - I-Mab Biopharma
Official Site Inspections
http://www.i-mabbiopharma.com Semrush global rank: 3.35 M Semrush visits lastest month: 4.74 K
Unable to get host informations!!!
More informations about "I-Mab Biopharma"
I-Mab | Corporate Profile - i-mabbiopharma.com
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.See details»
I-Mab Biopharma - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +862160578000 I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and …See details»
I-Mab | Investor Relations
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update. 2025.04.03See details»
I-Mab | I-Mab Provides Business and Corporate Updates and …
Efforts are already underway to work towards the commercialization strategy of "preparing the organization", "preparing the market" and "preparing the product" for felzartamab. In October …See details»
I-Mab Biopharma - Overview, News & Similar companies - ZoomInfo
I-Mab Biopharma contact info: Phone number: (240) 745-6330 Website: www.i-mabbiopharma.com What does I-Mab Biopharma do? I-Mab Biopharma Co., Ltd. is a clinical …See details»
I-Mab | Board of Directors - i-mabbiopharma.com
From August 2011 to December 2013, Mr. Fu served as the general manager of the investment department at Far East Horizon International, a financial services organization. Mr. Fu served …See details»
I-Mab Biopharma Company Profile | Management and Employees …
[email protected]: 6: last: [email protected]: Your Questions, Our Answers Get Free Access to I-Mab Biopharma Contacts Info. What is I-Mab Biopharma revenue? I-Mab …See details»
I-Mab Biopharma Company Profile - Office Locations, Competitors …
Oct 29, 2024 I-Mab Biopharma has 3 employees across 4 locations and ¥27.64 m in annual revenue in FY 2023. See insights on I-Mab Biopharma including office locations, competitors, …See details»
I-Mab Biopharma: going global with innovative …
I-Mab Biopharma. Jielun Zhu, CFO, I-Mab Biopharma, Shanghai, China, Tel: +852 6277 4338, Website: www.i-mabbiopharma.comSee details»
I-MAB Biopharma Co., Ltd. - Drug pipelines, Patents, Clinical
Www.i-mabbiopharma.com. Public Company | 2016 | Maryland, United States | 100-250 | NASDAQ: IMAB | www.i-mabbiopharma.com. Last update 13 Apr 2025. Overview. Pipeline. …See details»
I-Mab | I-Mab Appoints Ruyi He and Rong Shao to Board of …
Jun 1, 2021 E-mail: [email protected] Office line: +86 21 6057 8000. Gigi Feng, Chief Communications Officer E-mail: [email protected] Office line: +86 21 …See details»
Wei Fu | Board Member - I-Mab
From August 2011 to December 2013, Mr. Fu served as the general manager of the investment department at Far East Horizon International, a financial services organization. Mr. Fu served …See details»
I-Mab Strengthens Management Team Designed to Accelerate …
Dec 20, 2021 - New appointments as part of the Company’s strategic development plans to accelerate transformation towards commercialization - Dr. Andrew Zhu, an internationally …See details»
I-Mab Biopharma information - Employees, Contact info
View information on-I-Mab Biopharma (i-mabbiopharma.com),Located in . Find over 46 employees information, adress, official website, private emails, phone numbers, revenue, …See details»
I-MAB Biopharma (Shanghai) Co., Ltd. - synapse.zhihuiya.com
Apr 1, 2025 了解I-MAB Biopharma (Shanghai) Co., Ltd. (天境生物科技（上海）有限公司)公司的药物管线，治疗领域，技术平台，以及它的21项临床试验, 20篇新闻，疾病领域:肿瘤，免疫系 …See details»
AbbVie and I-Mab Enter Into Global Strategic Partnership for ...
Sep 4, 2020 NORTH CHICAGO, Ill., and SHANGHAI, Sept. 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and I-Mab (Nasdaq: IMAB) announced today that AbbVie and I-Mab have …See details»
I-Mab | I-Mab Launches Discovery Initiative to Expand …
E-mail: [email protected] Office line: +86 21 6057 8000. Gigi Feng, Chief Communications Officer E-mail: [email protected] Office line: +86 21 6057 …See details»
I-Mab Provides Business and Corporate Updates and Reports …
Mar 31, 2023 The Company now maintains a lean and efficient global R&D organization with an extended cash runway for at least three years. Mitigating Potential Challenges from the …See details»
I-Mab-I-MAB Biopharma Co., Ltd.-企业详情-InvestGO数据库 …
查看医药魔方InvestGO®数据库I-Mab的公司信息。I-Mab（I-MAB Biopharma Co., Ltd.），公司简介：我们是一家专注特药的全球创新生物制药公司，致力于创新生物药的靶点生物学研究、抗 …See details»
I-Mab Provides Business and Corporate Updates and Reports …
Aug 31, 2021 E-mail: [email protected] Office line: +86 21 6057 8000. Gigi Feng, Chief Communications Officer E-mail: [email protected] Office line: +86 21 …See details»